Galectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to ...
October 20 2017 - 8:30AM
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of
therapeutics that target galectin proteins, announced today that
Dr. Raj Vuppalanchi of Indiana University will present a poster
demonstrating the use of vibration-controlled transient
elastography (VCTE) for non-invasively measuring liver stiffness
(LSM) as a proven surrogate for identifying the progression of
cirrhosis in patients with nonalcoholic steatohepatitis (NASH).
These data were collected from a 137 patient baseline subset
of Galectin Therapeutics’ Phase 2b NASH-CX trial of its
antifibrotic agent, GR-MD-02, in patients with compensated NASH
cirrhosis and portal hypertension. The study will be
presented at The Liver Meeting® in Washington D.C. on October
19-23, 2017 and is co-authored by investigators involved in the
NASH-CX trial. Topline results from the trial will be reported in
December, 2017.
Based on previous studies that showed a strong correlation
between hepatic venous pressure gradient (HVPG) and liver stiffness
measurement (LSM) as a valid predictor of the development of
complications from cirrhosis, investigators examined the potential
utility of VCTE to measure LSM in patients with NASH cirrhosis as
well as the ability to detect clinically significant portal
hypertension (CSPH) in this patient population.
Vibration-controlled transient elastography is a non-invasive
tool that measures the liver stiffness measurement (LSM)
reliably. Several studies have reported a good correlation
between LSM and HPVG and its ability to detect CPSH. “Measuring
HVPG is an invasive and expensive procedure that requires special
expertise, therefore, having a non-invasive diagnostic tool that
predicts HPVG is very valuable in the management of cirrhosis,”
said Peter Traber, M.D., president, chief executive officer and
chief medical officer of Galectin Therapeutics and co-investigator
of both studies. “This research suggests that LSM by VCTE is a
useful test for prognostication in patients with compensated NASH
cirrhosis with low MELD scores. It can non-invasively
identify patients who are at risk for complications of cirrhosis
and better target those who might need invasive diagnostics such as
HVPG and liver biopsy. Additionally, it can be used to help
identify subjects in clinical trials.”
Details for poster presentation at The Liver Meeting:
Friday, October 20, 2017Poster Session
I“Liver Stiffness Measured By Vibration Controlled
Transient Elastography Is An Excellent Surrogate for Identifying
Clinically Significant Portal Hypertension In Patients With
Compensated NASH Cirrhosis,” R. Vuppalanchi, et al. Abstract
#446.
Galectin Therapeutics anticipates to announce top-line results
from their NASH-CX trial in December 2017. Further information on
the NASH-CX trial is also available at www.clinicaltrials.gov
About Galectin Therapeutics Galectin
Therapeutics is dedicated to developing novel therapies to
improve the lives of patients with chronic liver and skin diseases
and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate-based
drug that inhibits the galectin-3 protein that is directly involved
in multiple inflammatory, fibrotic, and malignant diseases. The
lead development program is in non-alcoholic steatohepatitis (NASH)
with cirrhosis, the most advanced form of NASH related fibrosis.
This is the most common liver disease and one of the largest drug
development opportunities available today. Additional development
programs are for treatment of severe atopic dermatitis,
moderate-to-severe plaque psoriasis, and in combination
immunotherapy for advanced melanoma and other malignancies.
Galectin seeks to leverage extensive scientific and development
expertise as well as established relationships with external
sources to achieve cost-effective and efficient development.
Additional information is available
at www.galectintherapeutics.com.
Contact: Jack Callicutt, Chief Financial
Officer 678-620-3186 ir@galectintherapeutics.com
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Apr 2023 to Apr 2024